Nuclear receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
== Therapeutic relevance == Fundamental discoveries uncovering the biology of ferroptosis and translational studies showing the disease relevance of ferroptosis have motivated efforts to develop therapeutics that modulate ferroptosis. For example, Kojin Therapeutics and PTC Therapeutics are exploring ferroptosis modulation for treatment of cancer and Friedrich's ataxia. Ferroptosis has been implicated in a range of different diseases including cancer, ischemia/reperfusion injury (IRI), inflammation, neurodegeneration, and kidney injury.
Aspartic, glutamic, and metallo-proteases activate a water molecule, which performs a nucleophilic attack on the peptide bond to hydrolyze it. Serine, threonine, and cysteine proteases use a nucleophilic residue (usually in a catalytic triad). That residue performs a nucleophilic attack to covalently link the protease to the substrate protein, releasing the first half of the product. This covalent acyl-enzyme intermediate is then hydrolyzed by activated water to complete catalysis by releasing the second half of the product and regenerating the free enzyme
He called the bill "crony capitalism" and set several conditions for acceptance of the bill: "Companies must agree to issue warrants or equity stakes to the federal government; they must commit to not buying back their own stock, outsourcing American jobs overseas or repealing existing collective bargaining agreements; and they must remain neutral in any union organizing efforts". In April 2023, Sanders endorsed Biden in the 2024 United States presidential election, and after Biden withdrew from the race, Sanders endorsed Harris for president at the Democratic National Convention. Sanders attempted to appeal to pro-Palestinian critics of Harris by saying, "I promise you, after Kamala wins, we will together do everything that we can to change US policy toward Netanyahu", and emphasizing Donald Trump's policies on climate change, minimum wage, and tax cuts for the wealthy.
=== Related compounds === Isometheptene Methylhexanamine (1,3-DMAA) Tuaminoheptane 1,3-Dimethylbutylamine (DMBA) 1,4-Dimethylamylamine (1,4-DMAA) Iproheptine (N-isopropyloctodrine) Heptaminol (hydroxyoctodrine) Oenethyl
Sources: en.wikipedia.org
Since then the community has treated the ordinary fungal binomial as the correct name, whether the fungus is lichenised in nature or grown axenically in culture. While most authors still relied on a stand‑alone lichen framework, a few pioneers argued that lichens should be incorporated into the wider fungal system. John Axel Nannfeldt opened the door in 1932 by dividing the Ascomycota into "ascohymenial" and "ascolocular" lineages based on ascoma development and ascus wall structure, a paradigm that implicitly scattered lichen‑forming fungi across several ordinary ascomycete orders. Rolf Santesson took the first practical step in 1952: studying foliicolous (leaf-dwelling) lichens, he slotted them into Nannfeldt's ascomycete orders rather than the catch-all "Lichenes". Each genus went into an ordinary ascomycete order or family alongside non-lichenised fungi. Each genus thus sat alongside non‑lichenised relatives, showing that lichens required no special Linnaean compartment. This idea was bold for its time (challenging the status quo). Even by the mid-20th century, most lichen funga still treated "Lichenes" as a separate category — lichen specialists maintained their own journals, herbaria, and methods. True integration with mainstream fungal classification only gathered pace once modern molecular methods arrived. Even after it was superseded, Zahlbruckner's catalogue—tens of thousands of names—remained the baseline for later revisions. Within that framework, lichenologists were already aware of potential flaws.
== References == Carlsson, J.; Forssell Aronsson, E; Hietala, SO; Stigbrand, T; Tennvall, J; et al. (2003). "Tumour therapy with radionuclides: assessment of progress and problems". Radiotherapy and Oncology. 66 (2): 107–117. doi:10.1016/S0167-8140(02)00374-2. PMID 12648782. "Radioisotopes in Industry". World Nuclear Association. Archived from the original on 27 February 2013. Retrieved 2 May 2008. Martin, James (2006). Physics for Radiation Protection: A Handbook. John Wiley & Sons. p. 130. ISBN 978-3527406111.
In December 2019, the US Food and Drug Administration (FDA) announced that it learned that some metformin medicines manufactured outside the United States might contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA), classified as a probable human carcinogen, at low levels. Health Canada announced that it was assessing NDMA levels in metformin. The European Medicines Agency provided an update on NDMA in metformin. In February 2020, the FDA found NDMA levels in some tested metformin samples that did not exceed the acceptable daily intake. In February 2020, Health Canada announced a recall of Apotex immediate-release metformin, followed in March by recalls of Ranbaxy metformin and in March by Jamp metformin. In May 2020, the FDA asked five companies to voluntarily recall their sustained-release metformin products. The five companies were not named, but they were revealed to be Amneal Pharmaceuticals, Actavis Pharma, Apotex Corp, Lupin Pharma, and Marksans Pharma Limited in a letter sent to Valisure, the pharmacy that had first alerted the FDA to this contaminant in metformin via a Citizen Petition. In June 2020, the FDA posted its laboratory results showing NDMA amounts in metformin products it tested. It found NDMA in certain lots of ER metformin and is recommending companies recall lots with levels of NDMA above the acceptable intake limit of 96 nanograms per day. The FDA is also collaborating with international regulators to share testing results for metformin.
Sources: en.wikipedia.org
7-Acetoxymitragynine is an opioid drug which is a semi-synthetic derivative of 7-hydroxymitragynine, a natural product derived from the South-East Asian tree known as kratom. It can be derived by acetylation of the hydroxyl group of 7-hydroxymitragynine, for instance with acetic anhydride, but can also be produced directly from mitragynine by reaction with Lead(IV) acetate. Unlike heroin, 7-acetoxymitragynine is less potent than 7-hydroxymitragynine, but nevertheless retains opioid activity. However It is not commonly or specifically found nor sold.
== Organisation == NCCD is overseen by a Governing Council and an Executive Committee, with equal representation of public and private sectors, chaired by the Secretary (A&C, Ministry of Agriculture). The principal executive of this body was originally conceived as its Director who would implement the decisions of the Executive Body. The first Director of NCCD was Mr. Sanjeev Chopra, a Joint Secretary in the Ministry of Agriculture. However, in keeping with the technical domain requirements, the governing bodies initially decided to invite an established leader from the private sector as a chief advisor to assist in incubating the body and develop a roadmap. In this initial stage, various concept level revisions were proposed regarding cold chain and the requirements to make it future ready. In these years, India's horticultural production also overtook that in food grains. Subsequently, in 2014 the Governing Council decided that this body required to be strengthened with relevant domain expertise. It restructured the organization and added the position of Chief Executive Officer, to be filled by an industry stalwart with hands-on domain experience. The government officer nominated Director, was thereafter to provide administration support, with the professional Chief Executive Officer responsible to provide executive and technical direction. Capt. Pawanexh Kohli was the first Chief Advisor and the founding Chief Executive Officer of NCCD and headed this organization for its first eight years from 2012 to 2020.
== Applications == Due to the high porosity and low density, graphene aerogel has been explored as a potential replacement in flight balloons. The large degree of recoverable compressibility and overall stiffness of the structure has been used in studies in graphene sponges capable of holding 1000× its weight in liquid while recovering all of the absorbed liquid without structural damage to the sponge due to the elasticity of the graphene structure. This has environmental implications, potentially contributing to cleanup of offshore oil spills. It can also be used to gather dust from the tails of comets.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.